Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, has raised £250 million in funding. This brings the total amount raised by OSE to more than £850 million.
The fundraising involved a diverse group of international investors, with strong participation from existing and new blue-chip investors, sovereign wealth funds, family offices, pension funds, and asset managers.
The new cash will enable the company to identify further exceptional science projects from the University of Oxford, providing initial funding, hands-on support and access to expert networks and startup infrastructure, to create new spinouts across life sciences, health tech, and deep tech.
In the future, OSE will continue to support its existing and maturing portfolio, deploying increasingly large amounts of capital in later-stage funding rounds. This ability to provide scaleup capital is crucial for OSE to enable its businesses to advance through key development milestones, maximising their chances of success and increasing potential returns and impact.
Alexis Dormandy, CEO of OSE said: “This fundraise comes at an exciting and pivotal time for OSE. We have built a talented team and proved our model of translating ground-breaking science into a diverse portfolio of transformational businesses. Our companies are making remarkable breakthroughs from cancer, heart failure and infectious diseases, to climate change, food security and quantum computing.”
OSE has invested in over 80 ambitious companies built on Oxford science since it was created in 2015. It has committed £0.5 billion and attracted over £1 billion from blue-chip, global co-investors. To date OSE has helped progress 27 companies from seed to Series A and 21 to Series B and beyond, including 2 IPOs and 5 trade exits.